Diabetic Retinopathy Market Size Set For Rapid Growth, To Reach Around USD 15.33 billion by 2032
Zion Market Research has published a new report titled “Diabetic Retinopathy Market by Type (Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy) and by Management (Vitrectomy, Anti-VEGF Therapy, Laser Surgery, and Intraocular Steroid Injection): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024– 2032”.
According to the report, The global diabetic retinopathy market size was worth around USD 8.76 billion in 2023 and is predicted to grow to around USD 15.33 billion by 2032 with a compound annual growth rate (CAGR) of roughly 6.41% between 2024 and 2032.
Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of vision loss and blindness among working-age adults worldwide. The diabetic retinopathy market encompasses a range of diagnostic and treatment options aimed at preventing, detecting, and managing DR and its complications. Here's an overview of key aspects of the diabetic retinopathy market:
Market Overview: The diabetic retinopathy market is driven by the increasing prevalence of diabetes globally, particularly in low- and middle-income countries, where access to eye care services may be limited. DR imposes a significant economic burden on healthcare systems due to the costs associated with vision loss, disability, and treatment. Early detection and intervention are critical in preventing vision loss and improving patient outcomes.
Types of Diabetic Retinopathy: Diabetic retinopathy can be classified into two main types:
Non-proliferative Diabetic Retinopathy (NPDR): Characterized by microvascular abnormalities such as retinal hemorrhages, microaneurysms, intraretinal microvascular abnormalities (IRMAs), and venous beading.Proliferative Diabetic Retinopathy (PDR): Involves the growth of abnormal blood vessels on the retina, which can lead to retinal detachment, vitreous hemorrhage, and vision loss.
Diagnostic Technologies: Various imaging and diagnostic modalities are used for the detection and monitoring of diabetic retinopathy, including:
Fundus Photography: Captures high-resolution images of the retina to detect signs of DR such as hemorrhages, exudates, and neovascularization.
Optical Coherence Tomography (OCT): Provides detailed cross-sectional images of retinal layers to assess macular thickness, detect macular edema, and monitor disease progression.
Fluorescein Angiography (FA): Involves the injection of a fluorescent dye into the bloodstream to visualize retinal blood vessels and detect areas of leakage or neovascularization.
Fundus Autofluorescence (FAF): Evaluates metabolic changes in the retina by measuring the fluorescence emitted by retinal pigments, helping to assess retinal health and detect early signs of DR.
Diabetes obstructs the ability to store and use sugar in the body. High amounts of sugar in the blood can damage multiple organs in the body. Diabetes can lead to many complications when left untreated. Minor complications include hyperosmolar hyperglycemic state or diabetic ketoacidosis. It can lead to other long-term complications like chronic kidney disease, cardiovascular diseases, stroke, and eye damage. Diabetic retinopathy is a complication that affects the eyes of diabetic people. Incessant elevated blood sugar due to diabetes is linked with impairment of small blood vessels present in the retina. Diabetic retinopathy can induce retinal blood vessels to hemorrhage or cause fluid leakage. People suffering from diabetes for more than 20 years are at a very high risk of developing diabetic retinopathy. Diabetic retinopathy does not show early signs of warning. The continued high blood sugar levels lead to damage of retinal blood vessels. The retinal blood vessels may swell and trickle. In certain cases, unusual blood vessels develop on the retina.
The symptoms of diabetic retinopathy include visibility of a high number of floaters, blurry vision, changing vision from blurry to clear, visibility of dark or blank areas in the vision field, poor night visibility, and faded appearance of colors. The severity of diabetic retinopathy can be minimized by taking constant eye check-ups, controlling blood sugar and blood pressure levels, and taking note of vision problems as and when they occur. Diabetic retinopathy can develop in people with both type 1 and 2 diabetes. Diabetic retinopathy progresses in four stages: mild non-proliferative retinopathy, moderate non-proliferative retinopathy, severe non-proliferative retinopathy, and proliferative diabetic retinopathy (PDR).
As per the WHO estimates, the diabetic population has grown from 108 million adults in 1980 to approximately 422 million adults in 2014. Furthermore, diabetic prevalence globally has doubled from 4.7% in 1980 to around 8.5% in2014. According to the Department of Assistive and Rehabilitative Services (DARS), around 78% diabetic retinopathy cases reported in 2013 might eventually cause a loss of vision. In U.K. diabetic retinopathy was the prominent cause of blindness in 2017, as per the Royal National Institute of Blind People (RNIB).
Growing baby boomer generation worldwide and rising occurrences of diabetes due to a sedentary lifestyle and an unhealthy diet are factors driving the growth of the global diabetic retinopathy market. Furthermore, delayed diagnosis of diabetes, refusal for treatment, the rising occurrence of vision loss due to diabetes, increasing healthcare expenditure, development of innovative treatments, and increasing research and development activities will further propel market growth. Various government and non-government organizations are trying to increase awareness regarding diabetic retinopathy and rapid advancements in the technology are acting as growth opportunities for the market players in the diabetic retinopathy market. However, lack of skilled ophthalmologists, non-availability of insurance facilities, and sub-standard primary infrastructure in developing regions might restrict the growth of the global diabetic retinopathy market.
The global diabetic retinopathy market is divided into type, management, and region. By type, the diabetic retinopathy market is bifurcated into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Non-proliferative diabetic retinopathy holds the majority market share, due to the rising number of diabetic retinopathy patients and increasing awareness. The management segment of the market includes vitrectomy, anti-VEGF therapy, laser surgery, and intraocular steroid injection. Anti-VEGF therapy segment holds the majority share of the management segment, due to its multiple benefits when compared to other therapies.
North America is projected to be the leading region in the forecast timeframe. The increasing prevalence of diabetic retinopathy and growing espousal of an unhealthy diet are driving the market growth in this region. Europe is projected to be the second largest market, owing to the increasing number of diabetic patients, rapid technological advancements, and increasing healthcare spending. The Asia Pacific is projected to propagate at a speedy rate in the forecast timeframe. Increasing geriatric population, growing diabetic population, and multiple governmental and non-governmental efforts will boost the market growth in this region. The Latin American market will develop at a significant rate in the forecast timeframe. The Middle Eastern and African countries are expected to experience moderate growth in the near future.
Diabetic Retinopathy Market: Competitive Analysis
The global diabetic retinopathy market is led by players like:
Regeneron Pharmaceuticals
Novartis
Allergan
Genentech
Bayer AG
Aerpio Pharmaceuticals
BCN Peptides
Ampio Pharmaceuticals
ThromboGenics
Alimera Sciences
Kowa Company
This report segments the global diabetic retinopathy market as follows:
Global Diabetic RetinopathyMarket: ByType
Non-Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Global Diabetic RetinopathyMarket: By Management
Vitrectomy
Anti-VEGF Therapy
Laser Surgery
Intraocular Steroid Injection
Global Diabetic RetinopathyMarket: By Region
North AmericaThe U.S.
EuropeUKFranceGermany
Asia PacificChinaJapanIndia
Latin AmericaBrazil
The Middle East and Africa
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Contact Us:
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com
Comments
Post a Comment